BICILLIN C-R 900/300 (penicillin g benzathine and penicillin g procaine) by Pfizer is mechanism of action penicillin g exerts a bactericidal action against penicillin-susceptible microorganisms during the stage of active multiplication. Approved for the treatment of infections, the treatment of the following in pediatric patients: moderately severe to severe infections of the upper-respiratory tract, scarlet fever and 3 more indications. First approved in 1953.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
BICILLIN C-R 900/300 is a fixed-dose combination of penicillin G benzathine and penicillin G procaine administered via intramuscular injection. It treats moderately severe to severe infections including upper-respiratory tract infections, scarlet fever, erysipelas, and skin/soft-tissue infections caused by susceptible streptococci, particularly in pediatric patients. The drug exerts bactericidal action by inhibiting bacterial cell wall peptidoglycan biosynthesis, rendering cells osmotically unstable and resulting in bacterial death.
Product approaching loss of exclusivity with moderate competitive pressure (30), indicating team focus likely shifting to lifecycle management and transition planning rather than growth initiatives.
Mechanism of Action Penicillin G exerts a bactericidal action against penicillin-susceptible microorganisms during the stage of active multiplication. It acts through the inhibition of biosynthesis of cell-wall peptidoglycan, rendering the cell wall osmotically unstable resulting in death of the…
Worked on BICILLIN C-R 900/300 at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moBICILLIN C-R 900/300 offers limited career growth opportunities due to its mature, LOE-approaching lifecycle and lack of active clinical development. Roles focus on legacy brand management, market access, and operational efficiency rather than innovation or market expansion.